November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Medigene to Host Virtual R&D Event on their Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
Sep 24, 2024, 15:01

Medigene to Host Virtual R&D Event on their Optimal 3S TCRs for TCR-Guided Precision Immunotherapies

Medigene AG, an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will host an R&D Event on their optimal 3S (specific, sensitive, and safe) TCRs for TCR-guided precision immunotherapies on Thursday, October 10, 2024, at 4.30 pm CET / 10:30 am ET. A live Q&A session will follow the formal presentations and discussions.

Management will discuss the advantages of the Company’s 3S TCRs across a wide range of modalities, including TCR-engineered T cell (TCR-T) therapies, TCR-guided T cell engager therapies (TCR-TCE), and TCR-natural killer cell therapies (TCR-NK).

Additionally, Principal Investigator of the EPITOME1015-I trial, Dr. David B. Zhen, Associate Professor at both the Fred Hutchinson Cancer Center and the University of Washington School of Medicine, will provide a comprehensive overview of the Company’s lead program, MDG1015. His presentation will highlight the innovative approach taken with Medigene’s lead third generation TCR-T therapy program, MDG1015, which targets the unmet needs that remain for treating solid tumors, despite recently approved first generation TCR-T therapies.

Medigene to Host Virtual R&D Event on their Optimal 3S TCRs for TCR-Guided Precision Immunotherapies

Finally, the presentation will cover Medigene’s proprietary End-to-End Platform, where multiple technologies can be deployed in a modular approach to generate multiple TCR-guided modalities, both cellular and antibody based, along with the latest advancements.

Attendees are invited to listen to the presentations and discussions as well as participate in the Q&A session.

Full details for the webcast and registration are as follows:

Date: October 10, 2024
Time: 4.30 pm CET / 10:30 am ET
Location: Virtual

Webcast registration here.

Following the call, an archived webcast will also be accessible on the Medigene website.

Other posts featuring Medigene AG.